HIV Infections Clinical Trial
Official title:
A Natural History Study of HIV Acquired in Infancy or Childhood
Background:
- About 10,000 children in the United States have been living with HIV infection since
birth. Little is known about the long-term effects of HIV infection and its treatment on
the growth and development of these children.
- Because of their disease, many children with HIV face additional difficulties with their
health, well-being and development, such as success in school and peer relationships.
Objectives:
- To better understand how HIV infection and the medicines used to treat it affect the
growth and development of children, adolescents and young adults who have been infected
since birth or when they were very young.
- To develop ways to improve the quality of life for these individuals.
Eligibility:
-HIV-infected patients who were followed by the pediatric HIV program in NCI as of December
2004, or an HIV-infected sibling of a participant.
Design:
- Periodic evaluation of pubertal development; bone mineralization; body composition and
fat distribution; liver, kidney and heart status; and behavioral, cognitive and academic
or vocational outcome of the study group. Evaluations include the following:
- Physical examinations, including height and weight measurements and skin-fold thickness
testing to measure body fat.
- Review of medical records and family history.
- Blood and urine tests, including pregnancy test in females who can bear children.
- DEXA scans (X-ray test to measure bone strength and how much fat, muscle and bone is in
the body).
- Neuropsychological testing, including evaluation of language, thinking and
problem-solving abilities.
- Magnetic resonance imaging (MRI): Test using a magnetic field and radio waves to examine
brain structure and function.
- Oral glucose tolerance test: Blood sampling before and one time after the subject drinks
a sugary solution to measure the body's ability to use sugar
Background:
Highly active antiretroviral therapy (HAART) has altered the natural history of HIV disease
in children.
The pediatric cohort in this country offers a tremendous opportunity to understand the effect
of HIV and ARTs on key developmental and maturational processes.
A thorough understanding of the impact of HIV and ARTs on these long-term processes is
extremely relevant as ART programs for HIV-infected children are being developed around the
world.
Objective:
To explore the clinical features and impact of HIV infection and antiretroviral therapy in an
HIV-infected pediatric cohort.
Eligibility:
Known HIV disease and followed in the NCI pediatric HIV program as of December 2004, or
HIV-infected sibling of a participant.
Elgibility for the cardiac sub-study is expanded to include any person with HIV acquired in
infancy or young childhood who is older than 7 and meets other inclusion criteria.
Eligibility for cardiac sub-study will also include HIV uninfected subjects (18-30 years of
age) who will server as a control group.
Design:
Serial evaluations of pubertal development, bone mineralization, body composition and fat
distribution, hepatic, renal, and cardiac status, and behavioral, cognitive, and
academic/vocational outcome.
Findings may be shared with the multicenter Pediatric HIV/AIDS Cohort Study and lead to more
intensive, focused substudies.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |